Immunotherapy in MSI/dMMR Tumors in Perioperative Setting.

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

October 18, 2021

Primary Completion Date

November 30, 2025

Study Completion Date

October 31, 2029

Conditions
Localized Resectable TumorMSI/dMMR
Interventions
DRUG

Pembrolizumab

Administered intravenous (IV)

Trial Locations (17)

13273

Institut Paoli Calmettes, Marseille

21079

Centre Georges-Francois Leclerc, Dijon

34298

Institut du Cancer Val d'Aurelle, Montpellier

35042

Centre Eugène Marquis, Rennes

42270

CHU Saint Etienne, Saint-Etienne

59037

Hopital Huriez, Lille

63003

CHU Clermont-Ferrand, Clermont-Ferrand

67200

Institut de cancérologie Strasbourg Europe, Strasbourg

69008

Centre Léon Bérard, Lyon

75010

APHP Hôpital Saint-Louis, Paris

75014

Institut mutualiste Montsouris, Paris

75015

Hôpital Européen Georges Pompidou, Paris

75571

APHP - Hôpital Saint-Antoine, Paris

Groupe Hospitalier Diaconesses Croix Saint-Simon, Paris

80054

CHU Amiens Picardie, Amiens

86021

CHU Poitiers, Poitiers

06189

Centre Antoine Lacassagne, Nice

All Listed Sponsors
lead

Centre Leon Berard

OTHER